Skip to main content

Table 1 Demographic and clinical data of Chronic Hepatitis B (CHB)-associated Acute-on-Chronic Liver Failure (ACLF) patients (N = 12), treatment naive CHB patients (NA = 27)

From: Chronic hepatitis B carriers with acute on chronic liver failure show increased HBV surface gene mutations, including immune escape variants

  CHB-ACLF (HBeAg positive, N = 6) CHB-ACLF (HBeAg negative, N = 6) Treatment naïve CHB
Immune tolerance (N = 2) Immune active (N = 9) Inactive (N = 5) HBeAg negative hepatitis (N = 11)
Median age (range)/# male 49 (21–64)/6 52 (26–57)/5 28 (20–35)/1 47 (23–50)/2 52 (45–61)/1 43 (36–57)/11
Ethnicity 6 Chinese 6 Chinese 1 Chinese; 1 Eastern European 6 Chinese; 1 Tibetian; 1 Vietnam; 1 Indonesia 3 East- Europe; 1 Korean; 1 African 6 Chinese; 1 Lebanese; 2 Vietnam; 1 Fillipino; 1 Egyptian
Median HBV DNA (rang, log IU/mL) 5.7 (4.3–7.3) 3.7 (2.2–5.9) 8.5 (8.0–8.6) 8.0 (4.5–9.0) 3.1 (UD-3.6) 4.3 (2.9–6.2)
Median ALT (rang, U/L) 562 (23–1584) 112 (48–2347) 37 (20–33) 86 (27–353) 25 (14–48) 48 (20–106)
# HBeAg negative patients 0/6 6/6 0/2 0/9 5/5 11/11
Genotype 1 B; 3 C; 2 unknown 2 B; 2 C; 2 unknown 1 B, 1 D 3 B, 5 C, 1 D 1 A, 1 B, 1 C, 1 D, 1 E 4 B, 4 C, 2 D, 1E
Median HBsAg (rang, log IU/mL3) unknown unknown unknown 4.0 (2–9.8) 3.9 (2.7–5.1) 3.5 (1.6–9.1)
# Liver fibrosis 3/6 5/6 0/2 3/9 0/5 5/11
# History of NA treatment 1 LAM 4 LAM N/A NA N/A NA
# Surviral (4 weeks after onset) 2/6 2/6 All alive All alive All alive All alive
  1. UD undetectable